Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT07734415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Study identification
- NCT ID
- NCT07734415
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2026 (Actual)
- Primary completion
- Mar 2028 (Estimated)
- Completion
- Mar 2028 (Estimated)
- Last update posted
- Jul 29, 2026
2026 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Inmagene Site 1 | Lancaster | California | 93534 | — |
| Inmagene Site 23 | Los Angeles | California | 90095 | — |
| Inmagene Site 19 | Ocala | Florida | 34470 | — |
| Inmagene Site 4 | Tampa | Florida | 33609 | — |
| Inmagene Site 2 | Rolling Meadows | Illinois | 60008 | — |
| Inmagene Site 6 | Kew Gardens | New York | 11415 | — |
| Inmagene Site 21 | New York | New York | 10029 | — |
| Inmagene Site 11 | Woodbury | New York | 11797 | — |
| Inmagene Site 20 | Charlotte | North Carolina | 28277 | — |
| Inmagene Site 10 | Fargo | North Dakota | 58103 | — |
| Inmagene Site 9 | Columbus | Ohio | 43213 | — |
| Inmagene Site 5 | Mayfield Heights | Ohio | 44124 | — |
| Inmagene Site 3 | Portland | Oregon | 97210 | — |
| Inmagene Site 12 | Anderson | South Carolina | 29621 | — |
| Inmagene Site 8 | Southlake | Texas | 76092 | — |
| Inmagene Site 7 | Burien | Washington | 698168 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07734415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07734415 live on ClinicalTrials.gov.